NCT07469956 2026-03-13
Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer
Sun Yat-sen University
Phase 2 Not yet recruiting
Clinical Trials
16 trialsNCT07277322 2026-03-02
Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases
Icahn School of Medicine at Mount Sinai
Phase 1/2 Not yet recruiting
NCT06952621 2026-01-30
TD-NEOE3V3
Tang-Du Hospital
Phase 3 Not yet recruiting
NCT06283134 2026-01-07
A Clinical Study of BioTTT001 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer
China Medical University, China
Phase 1 Not yet recruiting
NCT07272291 2025-12-09
A Phase II Study of Toripalimab Plus Chemotherapy and Low-Dose Radiotherapy for Neoadjuvant Therapy-Refractory Esophageal Squamous Cell Carcinoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT07246330 2025-11-24
Stratified Treatment in Unresectable Locally Advanced ESCC Without Progression After Chemoimmunotherapy Induction Plus CCRT: Toripalimab Consolidation vs observation--a Prospective, Randomized, Controlled Phase III Multicenter Study
Tianjin Medical University Cancer Institute and Hospital
Phase 3 Not yet recruiting
NCT07177794 2025-09-17
EC-CRT-008
Sun Yat-sen University
Phase 3 Not yet recruiting
NCT07159217 2025-09-08
Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer
Peking Union Medical College Hospital
Phase 2 Not yet recruiting
NCT06751394 2024-12-27
TRACER
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 2 Not yet recruiting
NCT06588335 2024-09-19
BTLA Inhibitor (JS004) Combined with Toripalimab and Chemotherapy in the Perioperative Treatment of Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
Henan Provincial People's Hospital
Phase 2 Not yet recruiting
NCT06370754 2024-04-17
FD-IMPACT
Fudan University
Phase 1/2 Not yet recruiting
NCT06283121 2024-02-29
A Clinical Study of BioTTT001 in Combination With SOX and Toripalimab in Patients With Gastric Cancer
China Medical University, China
Phase 2 Not yet recruiting
NCT06080854 2023-10-12
AG Combined With Immunotherapy and SBRT in Patients With Potentially Resectable Pancreatic Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Not yet recruiting
NCT05996484 2023-08-21
Neoadjuvant Therapy of Anlotinib Combined With Toripalimab and Chemotherapy for Resectable Esophageal Carcinoma
Nanfang Hospital, Southern Medical University
Phase 2 Not yet recruiting
NCT05970627 2023-08-01
Perioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma
First Affiliated Hospital of Zhejiang University
Phase 2 Not yet recruiting
NCT05791136 2023-03-30
TREE
The Central Hospital of Lishui City
Phase 2 Not yet recruiting